Skip to main content

Advertisement

SpringerLink
Log in

Late-onset deep surgical-site infection after posterior lumbar interbody fusion in a patient treated with tocilizumab; unusual changes in inflammatory markers

  • Case Report
  • Published:
European Spine Journal Aims and scope Submit manuscript

Abstract

Purpose

To describe a case of late-onset deep surgical-site infection (SSI) after posterior lumbar interbody fusion in a patient treated with tocilizumab (TCZ) for rheumatoid arthritis (RA), with emphasis on the clinical symptoms and changes in inflammatory markers such as white blood cell (WBC) count and C-reactive protein (CRP) level.

Case report

A 74-year-old woman with 3-year history of RA underwent posterior lumbar interbody fusion at the L4/5/S1 level. After confirmation of no clinical symptom of SSI postoperatively, we decided to use TCZ for the patient after 2 months postoperatively. At 8 months after beginning of TCZ, she suffered from sudden onset of severe low back pain (LBP) with fever (38 °C) 1 day after administration of TCZ. Local tissues around the operative wound showed no sign of redness, warmth, or swelling. Increases in body temperature, WBC count, and CRP level were well suppressed by TCZ. Magnetic resonance imaging performed 2 weeks after onset of LBP revealed deep SSI. After surgical debridement and administration of the sensitive antibiotics, no clinical signs of recurrent spondylitis or osteolysis of vertebral body have been seen for 3 years.

Conclusions

As TCZ strongly suppresses inflammatory reactions, detecting deep SSI based on local and systemic findings and laboratory data is quite difficult. Care must be taken regarding SSI when patients treated with TCZ complain of long-lasting LBP after lumbar surgery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

References

  1. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, Alecock E, Lee J, Kremer J (2008) IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67:1516–1523. doi:10.1136/ard.2008.092932

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  2. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Murata N, van der Heijde D, Kishimoto T (2007) Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X-ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 66:1162–1167

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. Kishimoto T (2005) Interleukin-6: from basic science to medicine–40 years in immunology. Annu Rev Immunol 23:1–21

    Article  CAS  PubMed  Google Scholar 

  4. Choy EH, Isenberg DA, Garrood T et al (2002) Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 46:3143–3150

    Article  CAS  PubMed  Google Scholar 

  5. Smolen JS, Beaulieu A, Rubbert-Roth A et al (2008) Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371:987–997. doi:10.1016/S0140-6736(08)60453-5

    Article  CAS  PubMed  Google Scholar 

  6. Fujiwara H, Nishimoto N, Hamano Y, Asanuma N, Miki S, Kasayama S, Suemura M (2009) Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment: a report of two cases. Mod Rheumatol 19:64–68. doi:10.1007/s10165-008-0111-7

    Article  PubMed  Google Scholar 

  7. Momohara S, Hashimoto J, Tsuboi H et al (2013) Analysis of perioperative clinical features and complications after orthopaedic surgery in rheumatoid arthritis patients treated with tocilizumab in a real-world setting: results from the multicentre tocilizumab in perioperative period (TOPP) study. Mod Rheumatol 23:440–449. doi:10.1007/s10165-012-0683-0

    Article  CAS  PubMed  Google Scholar 

  8. Hirao M, Nampei A, Shi K, Yoshikawa H, Nishimoto N, Hashimoto J (2011) Diagnostic features of mild cellulitis phlegmon in patients with rheumatoid arthritis treated with tocilizumab: a report of two cases. Mod Rheumatol 21:673–677. doi:10.1007/s10165-011-0459-y

    Article  PubMed  Google Scholar 

  9. Nagamine R, Chen W, Hara T, Kondo K, Sugioka Y (2009) Immediate reduction of white blood cell count after tocilizumab administration was observed in some cases. Mod Rheumatol 19:348–350. doi:10.1007/s10165-009-0159-z

    Article  PubMed  Google Scholar 

  10. Cunningham ME, Girardi F, Papadopoulos EC, Cammisa FP (2006) Spinal infections in patients with compromised immune systems. Clin Orthop Relat Res 444:73–82

    Article  PubMed  Google Scholar 

  11. Mori S, Tomita Y, Horikawa T, Cho I, Sugimoto M (2008) Delayed spinal infection after laminectomy in a patient with rheumatoid arthritis interruptedly exposed to anti-tumor necrosis factor alpha agents. Clin Rheumatol 27:937–939. doi:10.1007/s10067-008-0869-1

    Article  PubMed  Google Scholar 

  12. Yurube T, Takahi K, Owaki H, Fuji T, Kurosaka M, Doita M (2010) Late infection of total knee arthroplasty inflamed by anti-TNFalpha, infliximab therapy in rheumatoid arthritis. Rheumatol Int 30:405–408. doi:10.1007/s00296-009-0948-x

    Article  CAS  PubMed  Google Scholar 

  13. Oe K, Wada T, Ohno H, Kushida T, Iida H (2011) Salmonella septic arthritis following total knee arthroplasty for rheumatoid arthritis in a patient receiving etanercept. J Orthop Sci 16:258–262. doi:10.1007/s00776-011-0023-9

    Article  PubMed  Google Scholar 

  14. Koike R, Harigai M, Atsumi T et al (2009) Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod Rheumatol 19:351–357. doi:10.1007/s10165-009-0197-6

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Matsui T, Komiya A, Shimada K, Nakayama H, Tohma S (2009) Neutrophil CD64 as a marker of infection in patients treated with tocilizumab. Mod Rheumatol 19:696–697. doi:10.1007/s10165-009-0223-8

    Article  PubMed  Google Scholar 

  16. Tamaki K, Kogata Y, Sugiyama D et al (2008) Diagnostic accuracy of serum procalcitonin concentrations for detecting systemic bacterial infection in patients with systemic autoimmune diseases. J Rheumatol 35:114–119

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

No funds were received in support of this work. No benefits in any form have been or will be received from a commercial party related directly or indirectly to the subject of this manuscript.

Conflict of interest

None of the authors has any potential conflict of interest.

Author information

Authors and Affiliations

  1. Department of Orthopedic Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, 5650871, Osaka, Japan

    Takahiro Makino & Takashi Kaito

  2. Department of Orthopedic Surgery, National Hospital Organization Osaka Minami Medical Center, 2-1 Kidohigashi, Kawachinagano, 5868521, Osaka, Japan

    Takahiro Makino, Takashi Kaito, Hiroyasu Fujiwara & Kazuo Yonenobu

  3. Department of Rheumatology, National Hospital Organization Osaka Minami Medical Center, 2-1 Kidohigashi, Kawachinagano, 5868521, Osaka, Japan

    Hideki Tsuboi

  4. Graduate School of Health Care Sciences, Jikei Institute, 1-2-8 Miyahara, Yodogawa Osaka, 5320003, Osaka, Japan

    Kazuo Yonenobu

Authors
  1. Takahiro Makino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takashi Kaito
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hideki Tsuboi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hiroyasu Fujiwara
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kazuo Yonenobu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takahiro Makino.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Makino, T., Kaito, T., Tsuboi, H. et al. Late-onset deep surgical-site infection after posterior lumbar interbody fusion in a patient treated with tocilizumab; unusual changes in inflammatory markers. Eur Spine J 23 (Suppl 2), 296–301 (2014). https://doi.org/10.1007/s00586-014-3317-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00586-014-3317-8

Keywords

Search

Navigation